Phase 2 × Myeloproliferative Disorders × Filgrastim × Clear all
NCT01010217 2020-03-25

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

M.D. Anderson Cancer Center

Phase 2 Completed
176 enrolled 18 charts
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT00053196 2016-07-01

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
82 enrolled
NCT00002718 2015-12-23

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
31 enrolled
NCT00005852 2012-12-11

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
NCT00301912 2012-10-02

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

University of California, San Francisco

Phase 2 Withdrawn
NCT00004899 2012-06-12

Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Northwestern University

Phase 2 Completed
NCT00055653 2011-03-07

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Roswell Park Cancer Institute

Phase 2 Completed
NCT00003116 2010-06-11

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Case Comprehensive Cancer Center

Phase 2 Completed
66 enrolled
NCT00003913 2010-04-02

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

Fred Hutchinson Cancer Center

Phase 2 Completed
390 enrolled